Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1276887

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1276887

Europe Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 380 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

The Europe non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 8.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Non-Hodgkin lymphoma diagnostics market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe non-Hodgkin lymphoma diagnostics market are:

Increased growth in the prevalence of Non-Hodgkin Lymphoma

Advancement in artificial intelligence in the diagnosis of Non-Hodgkin Lymphoma

Market Players:

Some of the major players operating in the Europe non-Hodgkin lymphoma diagnostics market are:

CANON MEDICAL SYSTEMS CORPORATION

Koninklijke Philips N.V.

Siemens Healthcare GmbH

Danaher.

Bio-Rad Laboratories, Inc.

General Electric Company

Sysmex Corporation

Grail

F. Hoffmann-La Roche

Neusoft Corporation

Agilent Technologies, Inc.

NeoGenomics Laboratories

Hologic, Inc

Integrated DNA Technologies, Inc.

CENTOGENE N.V.

Merit Medical Systems

Invitae Corporation

PerkinElmer Inc.

QIAGEN

GeneDx, LLC

Show more

TABLE OF CONTENTS

1 INTRODUCTION 84

  • 1.1 OBJECTIVES OF THE STUDY 84
  • 1.2 MARKET DEFINITION 84
  • 1.3 OVERVIEW OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 84
  • 1.4 LIMITATIONS 86
  • 1.5 MARKETS COVERED 87

2 MARKET SEGMENTATION 90

  • 2.1 MARKETS COVERED 90
  • 2.2 GEOGRAPHICAL SCOPE 91
  • 2.3 YEARS CONSIDERED FOR THE STUDY 92
  • 2.4 CURRENCY AND PRICING 92
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 93
  • 2.6 MULTIVARIATE MODELLING 96
  • 2.7 PRODUCT TYPE LIFELINE CURVE 96
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
  • 2.9 DBMR MARKET POSITION GRID 98
  • 2.10 MARKET APPLICATION COVERAGE GRID 99
  • 2.11 VENDOR SHARE ANALYSIS 100
  • 2.12 SECONDARY SOURCES 101
  • 2.13 ASSUMPTIONS 101

3 EXECUTIVE SUMMARY 102

4 PREMIUM INSIGHTS 105

  • 4.1 PESTEL ANALYSIS 106
  • 4.2 PORTER'S 5 FORCES 107

5 INDUSTRY INSIGHTS 108

6 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 109

7 MARKET OVERVIEW 111

  • 7.1 DRIVERS 113
    • 7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 113
    • 7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 113
    • 7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 113
    • 7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 114
  • 7.2 RESTRAINTS 114
    • 7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 114
    • 7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 115
  • 7.3 OPPORTUNITIES 116
    • 7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 116
    • 7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 116
    • 7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 116
  • 7.4 CHALLENGES 117
    • 7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 117
    • 7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 117
    • 7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 118

8 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 119

  • 8.1 OVERVIEW 120
  • 8.2 IMAGING 123
    • 8.2.1 COMPUTED TOMOGRAPHY (CT) 124
    • 8.2.2 CHEST X-RAY 124
    • 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 124
    • 8.2.4 ULTRASOUND 124
    • 8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 124
  • 8.3 BIOPSY 124
    • 8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 125
    • 8.3.2 CORE NEEDLE BIOPSY 125
  • 8.4 IMMUNOHISTOCHEMISTRY 125
  • 8.5 BIOMARKER TEST 126
    • 8.5.1 BETA 2-M 127
    • 8.5.2 LDH 127
    • 8.5.3 CA-125 127
    • 8.5.4 TP53 127
    • 8.5.5 NPM1 128
    • 8.5.6 OTHERS 128
  • 8.6 GENETIC TEST 128
  • 8.7 CYTOGENETICS 128
  • 8.8 LUMBAR PUNCTURE (SPINAL TAP) 129
  • 8.9 BLOOD TEST 130
  • 8.10 CYTOCHEMISTRY 130
  • 8.11 OTHERS 131

9 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 132

  • 9.1 OVERVIEW 133
  • 9.2 AGGRESSIVE LYMPHOMAS 135
    • 9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 136
      • 9.2.1.1 INSTRUMENT BASED PRODUCTS 137
      • 9.2.1.2 PLATFORM BASED PRODUCTS 137
      • 9.2.1.3 KITS AND REAGENTS 137
      • 9.2.1.4 OTHER CONSUMABLES 137
    • 9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 137
      • 9.2.2.1 INSTRUMENT BASED PRODUCTS 138
      • 9.2.2.2 PLATFORM BASED PRODUCTS 138
      • 9.2.2.3 KITS AND REAGENTS 138
      • 9.2.2.4 OTHER CONSUMABLES 138
    • 9.2.3 MANTLE CELL LYMPHOMA 138
      • 9.2.3.1 INSTRUMENT BASED PRODUCTS 139
      • 9.2.3.2 PLATFORM BASED PRODUCTS 139
      • 9.2.3.3 KITS AND REAGENTS 139
      • 9.2.3.4 OTHER CONSUMABLES 139
    • 9.2.4 PERIPHERAL T-CELL LYMPHOMA 139
      • 9.2.4.1 INSTRUMENT BASED PRODUCTS 140
      • 9.2.4.2 PLATFORM BASED PRODUCTS 140
      • 9.2.4.3 KITS AND REAGENTS 140
      • 9.2.4.4 OTHER CONSUMABLES 140
    • 9.2.5 LYMPHOBLASTIC LYMPHOMA 140
      • 9.2.5.1 INSTRUMENT BASED PRODUCTS 141
      • 9.2.5.2 PLATFORM BASED PRODUCTS 141
      • 9.2.5.3 KITS AND REAGENTS 141
      • 9.2.5.4 OTHER CONSUMABLES 141
    • 9.2.6 BURKITT LYMPHOMA 141
      • 9.2.6.1 INSTRUMENT BASED PRODUCTS 142
      • 9.2.6.2 PLATFORM BASED PRODUCTS 142
      • 9.2.6.3 KITS AND REAGENTS 142
      • 9.2.6.4 OTHER CONSUMABLES 142
  • 9.3 INDOLENT LYMPHOMAS 142
    • 9.3.1 FOLLICULAR LYMPHOMA 143
      • 9.3.1.1 INSTRUMENT BASED PRODUCTS 144
      • 9.3.1.2 PLATFORM BASED PRODUCTS 144
      • 9.3.1.3 KITS AND REAGENTS 144
      • 9.3.1.4 OTHER CONSUMABLES 144
    • 9.3.2 CUTANEOUS T-CELL LYMPHOMA 144
      • 9.3.2.1 INSTRUMENT BASED PRODUCTS 145
      • 9.3.2.2 PLATFORM BASED PRODUCTS 145
      • 9.3.2.3 KITS AND REAGENTS 145
      • 9.3.2.4 OTHER CONSUMABLES 145
    • 9.3.3 MARGINAL ZONE B CELL LYMPHOMA 145
      • 9.3.3.1 INSTRUMENT BASED PRODUCTS 146
      • 9.3.3.2 PLATFORM BASED PRODUCTS 146
      • 9.3.3.3 KITS AND REAGENTS 146
      • 9.3.3.4 OTHER CONSUMABLES 146
    • 9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 146
      • 9.3.4.1 INSTRUMENT BASED PRODUCTS 147
      • 9.3.4.2 PLATFORM BASED PRODUCTS 147
      • 9.3.4.3 KITS AND REAGENTS 147
      • 9.3.4.4 OTHER CONSUMABLES 147
    • 9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 147
      • 9.3.5.1 INSTRUMENT BASED PRODUCTS 148
      • 9.3.5.2 PLATFORM BASED PRODUCTS 148
      • 9.3.5.3 KITS AND REAGENTS 148
      • 9.3.5.4 OTHER CONSUMABLES 148

10 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 149

  • 10.1 OVERVIEW 150
  • 10.2 SCREENING 152
    • 10.2.1 INSTRUMENT BASED PRODUCTS 153
    • 10.2.2 PLATFORM BASED PRODUCTS 153
    • 10.2.3 KITS AND REAGENTS 154
    • 10.2.4 OTHER CONSUMABLES 154
  • 10.3 DIAGNOSTIC AND PREDICTIVE 154
    • 10.3.1 INSTRUMENT BASED PRODUCTS 155
    • 10.3.2 PLATFORM BASED PRODUCTS 155
    • 10.3.3 KITS AND REAGENTS 155
    • 10.3.4 OTHER CONSUMABLES 155
  • 10.4 PROGNOSTIC 155
    • 10.4.1 INSTRUMENT BASED PRODUCTS 156
    • 10.4.2 PLATFORM BASED PRODUCTS 156
    • 10.4.3 KITS AND REAGENTS 156
    • 10.4.4 OTHER CONSUMABLES 157
  • 10.5 RESEARCH 157
    • 10.5.1 INSTRUMENT BASED PRODUCTS 158
    • 10.5.2 PLATFORM BASED PRODUCTS 158
    • 10.5.3 KITS AND REAGENTS 158
    • 10.5.4 OTHER CONSUMABLES 158

11 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 159

  • 11.1 OVERVIEW 160
  • 11.2 STAGE IV 162
  • 11.3 STAGE I 163
  • 11.4 STAGE III 164
  • 11.5 STAGE II 165
  • 11.6 STAGE 0 166

12 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 167

  • 12.1 OVERVIEW 168
  • 12.2 FLUORESCENT IN SITU HYBRIDIZATION 170
  • 12.3 NEXT GENERATION SEQUENCING 171
  • 12.4 FLUORIMMUNOASSAY 172
  • 12.5 COMPARATIVE GENOMIC HYBRIDIZATION 173
  • 12.6 IMMUNOHISTOLOCHEMICAL 173
  • 12.7 OTHER 174

13 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 175

  • 13.1 OVERVIEW 176
  • 13.2 INSTRUMENT BASED PRODUCTS 178
    • 13.2.1 IMAGING 179
    • 13.2.2 BIOPSY 179
  • 13.3 PLATFORM BASED PRODUCTS 180
    • 13.3.1 NEXT-GENERATION SEQUENCING 181
    • 13.3.2 MICROARRAYS 181
    • 13.3.3 PCR 181
    • 13.3.4 OTHERS 181
  • 13.4 KITS AND REAGENTS 181
    • 13.4.1 NON-HODGKIN LYMPHOMA PANELS 182
    • 13.4.2 IMMUNOHISTOCHEMISTRY STAINS 182
    • 13.4.3 OTHERS 182
  • 13.5 OTHER CONSUMABLES 183

14 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 184

  • 14.1 OVERVIEW 185
  • 14.2 HOSPITALS 187
  • 14.3 DIAGNOSTIC CENTERS 188
  • 14.4 CANCER RESEARCH CENTERS 189
  • 14.5 ACADEMIC INSTITUTES 190
  • 14.6 AMBULATORY SURGICAL CENTERS 190
  • 14.7 OTHERS 191

15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 192

  • 15.1 OVERVIEW 193
  • 15.2 DIRECT TENDER 195
  • 15.3 RETAIL SALES 196
  • 15.4 OTHERS 197

16 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 198

  • 16.1 EUROPE 199
    • 16.1.1 GERMANY 218
    • 16.1.2 UNITED KINGDOM 230
    • 16.1.3 FRANCE 242
    • 16.1.4 ITALY 254
    • 16.1.5 SPAIN 266
    • 16.1.6 RUSSIA 278
    • 16.1.7 NETHERLANDS 290
    • 16.1.8 SWITZERLAND 302
    • 16.1.9 BELGIUM 314
    • 16.1.10 TURKEY 326
    • 16.1.11 REST OF EUROPE 338

17 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 339

  • 17.1 COMPANY SHARE ANALYSIS: EUROPE 339

18 SWOT ANALYSIS 340

19 EUROPE NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 341

  • 19.1 CANON MEDICAL SYSTEMS CORPORATION 341
    • 19.1.1 COMPANY SNAPSHOT 341
    • 19.1.2 REVENUE ANALYSIS 341
    • 19.1.3 COMPANY SHARE ANALYSIS 342
    • 19.1.4 PRODUCT PORTFOLIO 342
    • 19.1.5 RECENT DEVELOPMENT 342
  • 19.2 KONINKLIJKE PHILIPS N.V. 343
    • 19.2.1 COMPANY SNAPSHOT 343
    • 19.2.2 REVENUE ANALYSIS 343
    • 19.2.3 COMPANY SHARE ANALYSIS 344
    • 19.2.4 PRODUCT PORTFOLIO 344
    • 19.2.5 RECENT DEVELOPMENTS 344
  • 19.3 SIEMENS HEALTHCARE GMBH 345
    • 19.3.1 COMPANY SNAPSHOT 345
    • 19.3.2 REVENUE ANALYSIS 345
    • 19.3.3 COMPANY SHARE ANALYSIS 346
    • 19.3.4 PRODUCT PORTFOLIO 346
    • 19.3.5 RECENT DEVELOPMENT 347
  • 19.4 DANAHER. 348
    • 19.4.1 COMPANY SNAPSHOT 348
    • 19.4.2 REVENUE ANALYSIS 348
    • 19.4.3 COMPANY SHARE ANALYSIS 349
    • 19.4.4 PRODUCT PORTFOLIO 349
    • 19.4.5 RECENT DEVELOPMENTS 350
  • 19.5 BIO-RAD LABORATORIES, INC. 351
    • 19.5.1 COMPANY SNAPSHOT 351
    • 19.5.2 REVENUE ANALYSIS 351
    • 19.5.3 COMPANY SHARE ANALYSIS 352
    • 19.5.4 PRODUCT PORTFOLIO 352
    • 19.5.5 RECENT DEVELOPMENT 352
  • 19.6 AGILENT TECHNOLOGIES, INC. 353
    • 19.6.1 COMPANY PROFILE 353
    • 19.6.2 REVENUE ANALYSIS 353
    • 19.6.3 PRODUCT PORTFOLIO 354
    • 19.6.4 RECENT DEVELOPMENT 354
  • 19.7 CENTOGENE N.V. 355
    • 19.7.1 COMPANY SNAPSHOT 355
    • 19.7.2 PRODUCT PORTFOLIO 355
    • 19.7.3 RECENT DEVELOPMENT 355
Show more
  • 19.8 F. HOFFMANN- LA ROCHE LTD 356
    • 19.8.1 COMPANY SNAPSHOT 356
    • 19.8.2 REVENUE ANALYSIS 356
    • 19.8.3 PRODUCT PORTFOLIO 357
    • 19.8.4 RECENT DEVELOPMENTS 357
  • 19.9 GENERAL ELECTRIC COMPANY 358
    • 19.9.1 COMPANY SNAPSHOT 358
    • 19.9.2 REVENUE ANALYSIS 358
    • 19.9.3 PRODUCT PORTFOLIO 359
    • 19.9.4 RECENT DEVELOPMENTS 359
  • 19.10 GENEDX, LLC 360
    • 19.10.1 COMPANY SNAPSHOT 360
    • 19.10.2 PRODUCT PORTFOLIO 360
    • 19.10.3 RECENT DEVELOPMENT 360
  • 19.11 GRAIL 361
    • 19.11.1 COMPANY PROFILE 361
    • 19.11.2 PRODUCT PORTFOLIO 361
    • 19.11.3 RECENT DEVELOPMENT 361
  • 19.12 HOLOGIC INC. 362
    • 19.12.1 COMPANY SNAPSHOT 362
    • 19.12.2 REVENUE ANALYSIS 362
    • 19.12.3 PRODUCT PORTFOLIO 363
    • 19.12.4 RECENT DEVELOPMENT 363
  • 19.13 INVITAE CORPORATION 364
    • 19.13.1 COMPANY PROFILE 364
    • 19.13.2 REVENUE ANALYSIS 364
    • 19.13.3 PRODUCT PORTFOLIO 365
    • 19.13.4 RECENT DEVELOPMENT 365
  • 19.14 NEUSOFT CORPORATION 366
    • 19.14.1 COMPANY SNAPSHOT 366
    • 19.14.2 REVENUE ANALYSIS 366
    • 19.14.3 PRODUCT PORTFOLIO 367
    • 19.14.4 RECENT DEVELOPMENT 367
  • 19.15 NEOGENOMICS LABORATORIES 368
    • 19.15.1 COMPANY SNAPSHOT 368
    • 19.15.2 REVENUE ANALYSIS 368
    • 19.15.3 PRODUCT PORTFOLIO 369
    • 19.15.4 RECENT DEVELOPMENTS 369
  • 19.16 PERKINELMER INC 370
    • 19.16.1 COMPANY PROFILE 370
    • 19.16.2 REVENUE ANALYSIS 370
    • 19.16.3 PRODUCT PORTFOLIO 371
    • 19.16.4 RECENT DEVELOPMENT 371
  • 19.17 QIAGEN 372
    • 19.17.1 COMPANY SNAPSHOT 372
    • 19.17.2 REVENUE ANALYSIS 372
    • 19.17.3 PRODUCT PORTFOLIO 373
    • 19.17.4 RECENT DEVELOPMENT 373
  • 19.18 SYSMEX CORPORATION 374
    • 19.18.1 COMPANY SNAPSHOT 374
    • 19.18.2 REVENUE ANALYSIS 374
    • 19.18.3 PRODUCT PORTFOLIO 375
    • 19.18.4 RECENT DEVELOPMENTS 375

20 QUESTIONNAIRE 376

21 RELATED REPORTS 380

LIST OF TABLES

  • TABLE 1 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 77
  • TABLE 2 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 78
  • TABLE 3 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 78
  • TABLE 4 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
  • TABLE 5 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 80
  • TABLE 6 EUROPE IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
  • TABLE 7 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 8 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 82
  • TABLE 9 EUROPE GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
  • TABLE 10 EUROPE CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 11 EUROPE LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 12 EUROPE BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
  • TABLE 13 EUROPE CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
  • TABLE 14 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
  • TABLE 15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 90
  • TABLE 16 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
  • TABLE 17 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 91
  • TABLE 18 EUROPE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 92
  • TABLE 19 EUROPE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 93
  • TABLE 20 EUROPE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 94
  • TABLE 21 EUROPE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 95
  • TABLE 22 EUROPE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 96
  • TABLE 23 EUROPE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 97
  • TABLE 24 EUROPE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
  • TABLE 25 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 26 EUROPE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 99
  • TABLE 27 EUROPE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 100
  • TABLE 28 EUROPE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 101
  • TABLE 29 EUROPE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 102
  • TABLE 30 EUROPE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 103
  • TABLE 31 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 107
  • TABLE 32 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
  • TABLE 33 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 108
  • TABLE 34 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 109
  • TABLE 35 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 110
  • TABLE 36 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
  • TABLE 37 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 111
  • TABLE 38 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
  • TABLE 39 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 113
  • TABLE 40 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 117
  • TABLE 41 EUROPE STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
  • TABLE 42 EUROPE STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
  • TABLE 43 EUROPE STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
  • TABLE 44 EUROPE STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION 120
  • TABLE 45 EUROPE STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
  • TABLE 46 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 125
  • TABLE 47 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
  • TABLE 48 EUROPE NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 49 EUROPE FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 50 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 51 EUROPE IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 52 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 53 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 133
  • TABLE 54 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
  • TABLE 55 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 134
  • TABLE 56 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
  • TABLE 57 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 136
  • TABLE 58 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
  • TABLE 59 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 137
  • TABLE 60 EUROPE OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)) 138
  • TABLE 61 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 142
  • TABLE 62 EUROPE HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 143
  • TABLE 63 EUROPE DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
  • TABLE 64 EUROPE CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
  • TABLE 65 EUROPE ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
  • TABLE 66 EUROPE AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 67 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 68 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 150
  • TABLE 69 EUROPE DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 151
  • TABLE 70 EUROPE RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 151
  • TABLE 71 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 152
  • TABLE 72 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 160
  • TABLE 73 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 74 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 75 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 76 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 77 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 162
  • TABLE 78 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 79 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 80 EUROPE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 163
  • TABLE 81 EUROPE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
  • TABLE 82 EUROPE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
  • TABLE 83 EUROPE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
  • TABLE 84 EUROPE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
  • TABLE 85 EUROPE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
  • TABLE 86 EUROPE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 87 EUROPE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
  • TABLE 88 EUROPE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
  • TABLE 89 EUROPE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
  • TABLE 90 EUROPE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 91 EUROPE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 92 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 93 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
  • TABLE 94 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 168
  • TABLE 95 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 168
  • TABLE 96 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
  • TABLE 97 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 169
  • TABLE 98 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 169
  • TABLE 99 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 169
  • TABLE 100 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 169
  • TABLE 101 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 170
  • TABLE 102 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 170
  • TABLE 103 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 170
  • TABLE 104 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
  • TABLE 105 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
  • TABLE 106 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
  • TABLE 107 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
  • TABLE 108 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 172
  • TABLE 109 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 172
  • TABLE 110 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 111 GERMANY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 112 GERMANY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 113 GERMANY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 114 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 174
  • TABLE 115 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 116 GERMANY AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 117 GERMANY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
  • TABLE 118 GERMANY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 176
  • TABLE 119 GERMANY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 176
  • TABLE 120 GERMANY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 176
  • TABLE 121 GERMANY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 177
  • TABLE 122 GERMANY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 177
  • TABLE 123 GERMANY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 124 GERMANY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 178
  • TABLE 125 GERMANY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 178
  • TABLE 126 GERMANY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 178
  • TABLE 127 GERMANY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
  • TABLE 128 GERMANY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
  • TABLE 129 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
  • TABLE 130 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
  • TABLE 131 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 180
  • TABLE 132 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 180
  • TABLE 133 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
  • TABLE 134 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 181
  • TABLE 135 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 181
  • TABLE 136 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 181
  • TABLE 137 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 181
  • TABLE 138 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 182
  • TABLE 139 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 182
  • TABLE 140 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 182
  • TABLE 141 GERMANY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 183
  • TABLE 142 GERMANY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 183

LIST OF FIGURES

  • FIGURE 1 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 44
  • FIGURE 2 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION 47
  • FIGURE 3 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS 48
  • FIGURE 4 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 49
  • FIGURE 5 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 49
  • FIGURE 6 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING 50
  • FIGURE 7 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 51
  • FIGURE 8 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 52
  • FIGURE 9 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 53
  • FIGURE 10 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 54
  • FIGURE 11 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 58
  • FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 59
  • FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028 59
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 66
  • FIGURE 15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022 74
  • FIGURE 16 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 75
  • FIGURE 17 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 75
  • FIGURE 18 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 76
  • FIGURE 19 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022 87
  • FIGURE 20 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION) 88
  • FIGURE 21 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030) 88
  • FIGURE 22 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE 89
  • FIGURE 23 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022 104
  • FIGURE 24 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 105
  • FIGURE 25 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030) 105
  • FIGURE 26 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE 106
  • FIGURE 27 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022 114
  • FIGURE 28 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION) 115
  • FIGURE 29 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030) 115
  • FIGURE 30 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE 116
  • FIGURE 31 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022 122
  • FIGURE 32 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 123
  • FIGURE 33 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030) 123
  • FIGURE 34 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE 124
  • FIGURE 35 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022 130
  • FIGURE 36 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 131
  • FIGURE 37 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030) 131
  • FIGURE 38 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE 132
  • FIGURE 39 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022 139
  • FIGURE 40 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 140
  • FIGURE 41 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 140
  • FIGURE 42 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 141
  • FIGURE 43 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022 147
  • FIGURE 44 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 148
  • FIGURE 45 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 148
  • FIGURE 46 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 149
  • FIGURE 47 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 154
  • FIGURE 48 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 156
  • FIGURE 49 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 156
  • FIGURE 50 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 157
  • FIGURE 51 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 158
  • FIGURE 52 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 293
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!